Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. VP of IP, CSO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,795 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 2,500 · Balance 19,795 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 18,637 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 1,158 · Balance 18,637 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 2,500 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2024 Filed Mar 14, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,884 | $12.98 | $50,414.32 |
DisclosureSEC source: 0001104659-24-034563 · tm248830-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-24-028785 · tm247055-35_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $30.21 | $151,050.00 |
DisclosureSEC source: 0001104659-24-028785 · tm247055-35_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.13 to $30.35. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $9.13 | $45,650.00 |
DisclosureSEC source: 0001104659-24-028785 · tm247055-35_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028275 · tm247055-21_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 638 | $29.06 | $18,540.28 |
DisclosureSEC source: 0001104659-24-028275 · tm247055-21_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,570 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028275 · tm247055-21_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,208 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027578 · tm247055-14_4seq1.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-02-22 F6 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027578 · tm247055-14_4seq1.xml · derivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F5 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027578 · tm247055-14_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 750 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 372 | $27.94 | $10,393.68 |
DisclosureSEC source: 0001104659-24-027578 · tm247055-14_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,958 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027578 · tm247055-14_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,330 F1 · balance_after: Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| September 07, 2023 Filed Sep 7, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-098986 · tm2325321-3_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on February 23, 2023. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| September 07, 2023 Filed Sep 7, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,182 | $32.10 | $37,942.20 |
DisclosureSEC source: 0001104659-23-098986 · tm2325321-3_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,165 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting. Read SEC document |
| September 07, 2023 Filed Sep 7, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-098986 · tm2325321-3_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on February 23, 2023. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-095388 · tm2324859-1_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-059838 · tm2315575-1_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on April 30, 2021. F2 · derivative.exercise_date: On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F2 · derivative.expiration_date: On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-059838 · tm2315575-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on April 30, 2021. Read SEC document |
| May 04, 2023 Filed May 8, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-057225 · tm2314899-1_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires not disclosed F1 · derivative.exercise_date: On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F1 · derivative.expiration_date: On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044662 · tm2312277-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,747 F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on May 3, 2022. F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on May 3, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026089 · tm237737-21_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026089 · tm237737-21_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025373 · tm237737-10_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025373 · tm237737-10_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,247 F1 · balance_after: Includes an aggregate of 853 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,826 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-23-005058 · tm233672-4_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 4,826 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 4,826 | $39.92 | $192,637.99 |
DisclosureSEC source: 0001104659-23-005058 · tm233672-4_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 4,826 | $9.13 | $44,061.38 |
DisclosureSEC source: 0001104659-23-005058 · tm233672-4_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 174 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-23-002317 · tm2233689-2_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,826 Underlying: Common Stock · 174 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 174 | $39.90 | $6,942.60 |
DisclosureSEC source: 0001104659-23-002317 · tm2233689-2_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 174 | $9.13 | $1,588.62 |
DisclosureSEC source: 0001104659-23-002317 · tm2233689-2_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-22-124160 · tm2231819-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $37.48 | $187,416.00 |
DisclosureSEC source: 0001104659-22-124160 · tm2231819-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.45 to $37.65, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $9.13 | $45,650.00 |
DisclosureSEC source: 0001104659-22-124160 · tm2231819-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-22-119181 · tm2230256-2_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,800 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on January 21, 2015. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 6,800 | $34.95 | $237,655.24 |
DisclosureSEC source: 0001104659-22-119181 · tm2230256-2_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.110, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 6,800 | $9.24 | $62,832.00 |
DisclosureSEC source: 0001104659-22-119181 · tm2230256-2_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-22-118708 · tm2230256-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 700 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on January 21, 2015. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 700 | $34.97 | $24,479.91 |
DisclosureSEC source: 0001104659-22-118708 · tm2230256-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.145, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 700 | $9.24 | $6,468.00 |
DisclosureSEC source: 0001104659-22-118708 · tm2230256-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| July 15, 2022 Filed Aug 5, 2022 20:31 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-086729 · tm2222645-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026883 · tm227622-8_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026883 · tm227622-8_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:17 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027397 · tm227764-4_4aseq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. F4 · derivative.expiration_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:17 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-027397 · tm227764-4_4aseq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:51 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026933 · tm217706-7_4seq1.xml · derivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-02-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2022. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024848 · a4.xml · derivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-02-21 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 21, 2021. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:27 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-19-010800 · a4.xml · derivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2020. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 4,393 | $59.90 | $263,153.00 |
DisclosureSEC source: 0001104659-18-043279 · a4.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.9000 to $59.9500, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 295 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-18-043279 · a4.xml · derivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 295 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on March 3, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,402 | $59.94 | $203,899.21 |
DisclosureSEC source: 0001104659-18-043279 · a4.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,393 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.9000 to $60.0250, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.